NEW YORK, Feb. 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Nevada on behalf of those who acquired BioVie, Inc ("BioVie" or the "Company") (NASDAQ:BIVI) securities during the period of August 5, 2021 through November 29, 2023, inclusive ("the Class Period"). Investors have until March 19, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
[Click here to learn more about the class action]
On November 8, 2023, the Company filed its quarterly report with the SEC on Form 10-Q for the quarter ended September 30, 2023. The Company disclosed that routine monitoring of data from its Phase 3 clinical trial of NE3108, a molecule developed to treat mild to moderate Alzheimer's Disease, "uncovered what appears to be potential scientific misconduct and significant non-compliance with GCPs and regulation at six sites," and that the "findings of potential scientific misconduct and significant GCP violations may call into question the rigor, robustness and validity of the entire data set for this study (NCT04669028) and may require additional clinical studies to confirm the final results of the ...
BIVI) Investors of Class Action Filing and Encourages Investors to Contact the Firm>Full story available on Benzinga.com